U.S. flag

An official website of the United States government

NM_002890.3(RASA1):c.1332+2T>G AND Capillary malformation-arteriovenous malformation syndrome

Germline classification:
Pathogenic (1 submission)
Last evaluated:
May 10, 2019
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001216670.16

Allele description [Variation Report for NM_002890.3(RASA1):c.1332+2T>G]

NM_002890.3(RASA1):c.1332+2T>G

Genes:
RASA1:RAS p21 protein activator 1 [Gene - OMIM - HGNC]
CCNH:cyclin H [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
5q14.3
Genomic location:
Preferred name:
NM_002890.3(RASA1):c.1332+2T>G
HGVS:
  • NC_000005.10:g.87353237T>G
  • NG_011650.1:g.89904T>G
  • NM_001364075.2:c.934-40442A>C
  • NM_002890.3:c.1332+2T>GMANE SELECT
  • NM_022650.3:c.801+2T>G
  • NC_000005.9:g.86649054T>G
  • NM_002890.2:c.1332+2T>G
Links:
dbSNP: rs1759410564
NCBI 1000 Genomes Browser:
rs1759410564
Molecular consequence:
  • NM_001364075.2:c.934-40442A>C - intron variant - [Sequence Ontology: SO:0001627]
  • NM_002890.3:c.1332+2T>G - splice donor variant - [Sequence Ontology: SO:0001575]
  • NM_022650.3:c.801+2T>G - splice donor variant - [Sequence Ontology: SO:0001575]

Condition(s)

Name:
Capillary malformation-arteriovenous malformation syndrome
Synonyms:
Capillary malformation-arteriovenous malformation
Identifiers:
MONDO: MONDO:0012016; MedGen: C1842180; OMIM: PS608354

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001388478Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(May 10, 2019)
germlineclinical testing

PubMed (3)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Splicing in action: assessing disease causing sequence changes.

Baralle D, Baralle M.

J Med Genet. 2005 Oct;42(10):737-48. Review.

PubMed [citation]
PMID:
16199547
PMCID:
PMC1735933

RASA1 mutations and associated phenotypes in 68 families with capillary malformation-arteriovenous malformation.

Revencu N, Boon LM, Mendola A, Cordisco MR, Dubois J, Clapuyt P, Hammer F, Amor DJ, Irvine AD, Baselga E, Dompmartin A, Syed S, Martin-Santiago A, Ades L, Collins F, Smith J, Sandaradura S, Barrio VR, Burrows PE, Blei F, Cozzolino M, Brunetti-Pierri N, et al.

Hum Mutat. 2013 Dec;34(12):1632-41. doi: 10.1002/humu.22431. Epub 2013 Oct 10.

PubMed [citation]
PMID:
24038909
See all PubMed Citations (3)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV001388478.5

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (3)

Description

For these reasons, this variant has been classified as Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in RASA1 are known to be pathogenic (PMID: 24038909). This variant has been observed to be de novo in an individual affected with clinical features of RASA1-related conditions (Invitae). This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 9 of the RASA1 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 26, 2024